Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CET
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
02/21 SAREPTA THERAPEUTICS, INC. (NASDAQ : SRPT) Files An 8-K Entry into a Material De..
02/19 GILEAD SCIENCES : Price gouging of lifesaving drugs raises alarms, threatens bud..
02/16 GILEAD SCIENCES : to Present at the RBC Capital Markets 2017 Global Healthcare C..
02/16 GILEAD SCIENCES : New Antiretrovirals Data Have Been Reported by Researchers at ..
02/16 GILEAD SCIENCES : Receives Approval in Canada for ODEFSEY™ for the Treatme..
02/15 GILEAD SCIENCES : Announces 144-Week Data Evaluating Safety and Efficacy of Genv..
02/14 Gilead challenges GSK with strong HIV drug data
02/14 GILEAD SCIENCES : Presents New Phase 2 Data on Bictegravir, an Investigational I..
02/14 GILEAD SCIENCES : Announces Findings from New Preclinical Study Evaluating Novel..
02/10 CYTODYN INC. : (CYDY) PRO 140 – A Promising Entry in the Treatment of HIV
More news
Sector news : Bio Therapeutic Drugs
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08:51a Gilead's M&A Growth Strategies Becoming Increasingly Limited
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 What Could Vemlidy Mean For Gilead?
02/21 GILEAD : The Catalyst We Were Waiting For?
02/21 Gilead Gets The Best Of Sarepta In $125M PRV Sale
Advertisement
Financials ($)
Sales 2017 24 644 M
EBIT 2017 15 598 M
Net income 2017 10 931 M
Finance 2017 306 M
Yield 2017 3,09%
P/E ratio 2017 8,88
P/E ratio 2018 9,39
EV / Sales 2017 3,69x
EV / Sales 2018 3,89x
Capitalization 91 287 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,8 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-3.24%91 287
AMGEN, INC.18.42%127 509
CELGENE CORPORATION3.19%92 920
REGENERON PHARMACEUTIC..1.23%39 421
ACTELION LTD22.45%28 891
VERTEX PHARMACEUTICALS..17.48%21 467
More Results